Cargando…

A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease

PURPOSE: NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. METHODS: SEECASE was a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tauber, Joseph, Wirta, David L., Sall, Kenneth, Majmudar, Parag A., Willen, Daniela, Krösser, Sonja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cornea 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330824/ https://www.ncbi.nlm.nih.gov/pubmed/33369937 http://dx.doi.org/10.1097/ICO.0000000000002622

Ejemplares similares

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial
por: Akpek, Esen K., et al.
Publicado: (2023)

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study
por: Steven, Philipp, et al.
Publicado: (2015)

A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study
por: Sheppard, John D., et al.
Publicado: (2021)

A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye
por: Gehlsen, Uta, et al.
Publicado: (2017)

Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease
por: Steven, Philipp, et al.
Publicado: (2017)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier, Edward, et al.
Publicado: (2017)

The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye
por: Trattler, William B, et al.
Publicado: (2017)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins, Gary, et al.
Publicado: (2020)

Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose
por: Cohen, Stephen, et al.
Publicado: (2014)

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
por: Torkildsen, Gail, et al.
Publicado: (2017)

Safety and Tolerability of an Eye Drop Based on 0.6% Povidone–Iodine Nanoemulsion in Dry Eye Patients
por: Oliverio, Giovanni William, et al.
Publicado: (2021)

The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye
por: Hovanesian, John A, et al.
Publicado: (2022)

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye
por: You, In Cheon, et al.
Publicado: (2018)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Efficacy of hyaluronic acid 0.3%, cyanocobalamin, electrolytes, and P-Plus in menopause patients with moderate dry eye disease
por: De-Hita-Cantalejo, Concepción, et al.
Publicado: (2021)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
por: Yeu, Elizabeth, et al.
Publicado: (2019)

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
por: Schultz, Clyde
Publicado: (2014)

Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye
por: Roszkowska, Anna Maria, et al.
Publicado: (2022)

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
por: Wirta, David, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease
por: Holland, Edward J, et al.
Publicado: (2022)

Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma
por: Madan Mohan, NT, et al.
Publicado: (2016)

Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome
por: Zheng, Na, et al.
Publicado: (2023)

Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment
por: Milner, Mark S., et al.
Publicado: (2017)

Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta, David, et al.
Publicado: (2011)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber, Joseph, et al.
Publicado: (2018)

Arthrobacter siccitolerans sp. nov., a highly desiccation-tolerant, xeroprotectant-producing strain isolated from dry soil
por: SantaCruz-Calvo, L., et al.
Publicado: (2013)

A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare(®) System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
por: Karpecki, Paul, et al.
Publicado: (2020)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

Safety bulletin SC 2006-03
Publicado: (2006)

South American Nothochrysinae (Neuroptera, Chrysopidae): I. Description of Nothochrysaehrenbergi sp. nov.
por: Tauber, Catherine A.
Publicado: (2019)

Evaluation of the rSP03B sero-strip, a newly proposed rapid test for canine exposure to Phlebotomus perniciosus, vector of Leishmania infantum
por: Willen, Laura, et al.
Publicado: (2018)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
por: McLaughlin, Patricia J., et al.
Publicado: (2019)

Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis
por: Hazarika, Ajit Kumar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7cgv0hkum8huaubu7pbao7o4oe